Clinical Trial

SG301 Safety Study in Subjects With Relapsed or Refractory Multiple Myeloma and Other Hematological Malignancies

Active, Not Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This is a Phase 1a/1b Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SG301 in Patients with Relapsed or Refractory Multiple Myeloma and Other Hematological Malignancies
Protocol Amendment History 1 change
minor Completion pushed: 2026-06-30 -> 2026-12-30 2026-08-12
Trial Details
NCT Number NCT04684108
Lead Sponsor Hangzhou Sumgen Biotech Co., Ltd.
Conditions Relapsed or Refractory Multiple Myeloma, Hematological Malignancy
Enrollment 61 participants
Start Date 2021-11-04
Primary Completion 2024-06-30 (estimated)
Study Completion 2026-12-30 (estimated)
Updated on ClinicalTrials.gov 2026-08-11